DM
Dr Mark Youssef
Global Head of Business Development and Licensing
HealxHealx Pipeline
| Drug | Indication | Phase |
|---|
| HLX-1502 | Neurofibromatosis Type 1 | Phase 2 |
| HLX-0213 | Neurofibromatosis Type 1 | Preclinical |
| HLX-4310 | Osteosarcoma | IND enabling |
| Undisclosed | Rare and Pediatric Oncology | AI Discovery |
| HLX-0206 | Fragile X Syndrome | AI Discovery |
| HLX-0553 | Angelman Syndrome | Preclinical |